Eric Solary - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Eric Solary's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Eric Solary
Verified
Associate Editor, Blood Cancer Journal
Beats
lifestyle,Automotive parenting, business fitness, industry outdoors, travel
Content
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
By Joseph Khoury, Eric Solary, Oussama Abla, Yassmine Akkari| Texas Medical Center@ To view the content in your browser, please download Adobe Reader or, alternately, you may Download the file to your hard drive. NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window
Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathways - Communications Biology
By Vincent Alcazer, Stéphane Depil, Aline Renneville, Dorothée Selimoglu-Buet, Raphael Itzykson, Lucie Laplane, Nathalie Droin, Eirini Trompouki, Eric Solary| Nature Verified AbstractChronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy affecting the elderly, for which therapeutic options are limited. DNA hypomethylating agents (HMAs) provide transient responses, failing to eradicate the malignant clone. Hematopoietic stem cell (HSC) aging involves heterochromatin reorganization, evidenced by alterations in histone marks H3K9me2 and H3K9me3. These repressive marks together with DNA methylation are essential for suppressing transposable elements (TEs)
Company Info
Blood Cancer Journal
Villejuif, Ile-de-France, France
+33 1 42 11 42 11